KNSA Kiniksa Pharmaceuticals Ltd
Price (delayed)
$25.25
Market cap
$1.8B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.15
Enterprise value
$1.71B
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of
Highlights
Kiniksa Pharmaceuticals's revenue has increased by 21% YoY and by 12% QoQ
KNSA's gross profit is up by 18% year-on-year and by 12% since the previous quarter
The EPS has dropped by 105% year-on-year
KNSA's net income has dropped by 104% year-on-year
Key stats
What are the main financial stats of KNSA
Market
Valuations
Earnings
Shares outstanding
71.24M
Market cap
$1.8B
Enterprise value
$1.71B
Price to book (P/B)
4.12
Price to sales (P/S)
5.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.05
Revenue
$338.93M
EBIT
-$18.02M
EBITDA
-$12.92M
Free cash flow
$30.34M
Per share
Balance sheet
Liquidity
EPS
-$0.15
Free cash flow per share
$0.43
Book value per share
$6.13
Revenue per share
$4.77
TBVPS
$7.4
Total assets
$542.43M
Total liabilities
$107.33M
Debt
$11.4M
Equity
$435.1M
Working capital
$216.73M
Debt to equity
0.03
Current ratio
3.57
Quick ratio
2.84
Net debt/EBITDA
6.8
Margins
Efficiency
Dividend
EBITDA margin
-3.8%
Gross margin
87.7%
Net margin
-3%
Operating margin
-8.1%
Return on assets
-2%
Return on equity
-2.4%
Return on invested capital
-5.5%
Return on capital employed
-3.9%
Return on sales
-5.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KNSA stock price
How has the Kiniksa Pharmaceuticals stock price performed over time
Intraday
-0.55%
1 week
3.74%
1 month
-2.88%
1 year
45.62%
YTD
43.96%
QTD
35.24%
Financial performance
How have Kiniksa Pharmaceuticals's revenue and profit performed over time
Revenue
$338.93M
Gross profit
$297.35M
Operating income
-$27.51M
Net income
-$10.23M
Gross margin
87.7%
Net margin
-3%
KNSA's operating income has dropped by 172% year-on-year but it is up by 10% since the previous quarter
KNSA's operating margin has dropped by 160% year-on-year but it is up by 20% since the previous quarter
KNSA's net income has dropped by 104% year-on-year
The net margin has dropped by 104% year-on-year
Growth
What is Kiniksa Pharmaceuticals's growth rate over time
Valuation
What is Kiniksa Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.12
P/S
5.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.05
The EPS has dropped by 105% year-on-year
KNSA's price to book (P/B) is 38% higher than its last 4 quarters average of 3.0 and 22% higher than its 5-year quarterly average of 3.4
Kiniksa Pharmaceuticals's equity has increased by 6% YoY
Kiniksa Pharmaceuticals's revenue has increased by 21% YoY and by 12% QoQ
The stock's price to sales (P/S) is 18% more than its last 4 quarters average of 4.5
Efficiency
How efficient is Kiniksa Pharmaceuticals business performance
KNSA's ROIC has plunged by 136% YoY but it is up by 18% from the previous quarter
The return on sales has dropped by 135% year-on-year but it is up by 25% since the previous quarter
Kiniksa Pharmaceuticals's return on assets has shrunk by 104% YoY
Kiniksa Pharmaceuticals's return on equity has shrunk by 104% YoY
Dividends
What is KNSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KNSA.
Financial health
How did Kiniksa Pharmaceuticals financials performed over time
KNSA's total liabilities is up by 48% year-on-year and by 22% since the previous quarter
KNSA's quick ratio is down by 36% YoY and by 20% QoQ
The debt is 97% smaller than the equity
The debt has declined by 16% year-on-year and by 6% since the previous quarter
Kiniksa Pharmaceuticals's equity has increased by 6% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.